It is made available under a CC-BY 4.0 International license .

1	Impact of community treatment with ivermectin for the control of scabies on the
2	prevalence of antibodies to Strongyloides stercoralis in children
3	
4	Michael Marks <sup>1,2</sup> ,Sarah Gwyn <sup>3</sup> , Hilary Toloka <sup>4</sup> , Christian Kositz <sup>1</sup> , James
5	Asugeni <sup>4</sup> , Rowena Asugeni <sup>4</sup> , Jason Diau <sup>4</sup> , John M Kaldor <sup>5</sup> , Lucia Romani <sup>5</sup> , Michelle
6	Redman-MacLaren <sup>6</sup> , David MacLaren <sup>6</sup> , Anthony W Solomon <sup>1,2</sup> , David CW Mabey <sup>1,</sup>
7	<sup>2</sup> Andrew C Steer <sup>7,8,9</sup> , Diana Martin <sup>3</sup>
8	
9	1 Clinical Research Department, Faculty of Infectious and Tropical Diseases,
10	London School of Hygiene & Tropical Medicine, Keppel Street, London, WC1E
11	7HT, United Kingdom
12	
13	2 Hospital for Tropical Diseases, University College London Hospitals NHS Trust,
14	London, WC1E 6JB, United Kingdom
15	
16	3 Division of Parasitic Diseases and Malaria, Centers for Disease Control and
17	Prevention, Atlanta, United States of America
18	
19	4 Atoifi Adventist Hospital, Atoifi, Malaita Province, Solomon Islands
20	
21	5 Kirby Institute, University of New South Wales, Sydney, Australia
22	
23	6 College of Medicine and Dentistry, James Cook University, Cairns, Queensland,
24	Australia
25	
26	7 Department of Paediatrics, University of Melbourne, Melbourne, Victoria,
27	Australia
28	
29	8 Department of General Medicine, Royal Children's Hospital, Melbourne,
30	Victoria, Australia
31	
32	9 Tropical Diseases Research Group, Murdoch Children's Research Institute,
33	Melbourne, Victoria, Australia

It is made available under a CC-BY 4.0 International license .

# 35 **Author for Correspondence**:

- 36 Michael Marks
- 37 Clinical Research Department,
- 38 Faculty of Infectious and Tropical Diseases,
- 39 London School of Hygiene & Tropical Medicine,
- 40 Keppel Street,
- 41 London, WC1E 7HT
- 42 United Kingdom
- 43 <u>michael.marks@lshtm.ac.uk</u>
- 44
- 45 **Running Title**:
- 46 Ivermectin MDA and Strongyloides
- 47
- 48 Key Words:
- 49 Scabies
- 50 Neglected tropical diseases
- 51 Ivermectin
- 52 Strongyloides
- 53
- 54
- 55
- 56
- 57

It is made available under a CC-BY 4.0 International license .

#### 58 Abstract

- 60 Prevalence of antibodies to *Strongyloides stercoralis* was measured in 0–12-year-
- olds using a bead-based immunoassay before and after ivermectin mass drug
- 62 administration (MDA) for scabies in the Solomon Islands. Seroprevalence was
- 63 9.3% before and 5.1% after MDA (p = 0.019), demonstrating collateral benefits
- 64 of scabies MDA in this setting.

- . 5

It is made available under a CC-BY 4.0 International license .

### 91 Introduction:

92 Strongyloides stercoralis, is unique among soil-transmitted helminths (STHs) in 93 its ability to complete its life cycle within the human host. S. stercoralis infection 94 is most commonly asymptomatic but may be associated with eosinophilia, 95 fatigue, diarrhoea and occasionally larva currens [1]. People with compromised 96 immune systems are at risk of potentially fatal hyperinfection syndrome [1]. 97 Albendazole or mebendazole are effective against other major STH species and 98 have been incorporated into mass drug administration (MDA) programs for 99 public health purposes. However, these drugs have limited efficacy for 100 strongyloidiasis, for which ivermectin is the first-line agent. 101 MDA with ivermectin is used widely to control a number of neglected tropical 102 diseases (NTDs), including lymphatic filariasis, onchocerciasis and, most 103 recently, scabies [2,3], but has so far not been adopted for *S. stercoralis* control. 104 Given the drug's broad anti-parasitic effect, MDA with ivermectin may have as a 105 collateral benefit the population-level control of *S. stercoralis*. Evaluation of *S.* 106 stercoralis control has been facilitated by serological assays that detect 107 antibodies against the NIE antigen, which is present in infective L3 larvae [4] 108 These antibodies likely indicate current or recent infection [5] and have high 109 sensitivity and specificity compared to stool examination<sup>[4]</sup>. The NIE antigen has 110 been adapted for use in the Luminex platform, allowing large scale screening of 111 populations using dried blood spots [6]. 112 113 In the context of a community-randomized trial evaluating the addition of

azithromycin to ivermectin-based MDA for scabies and impetigo in the Solomon

- 115 Islands, we measured the prevalence of antibody responses to the *S. stercoralis*
- 116 NIE antigen before and after MDA.

117

# 118 <u>Methods:</u>

- 119 The trial of MDA for scabies and impetigo has been described elsewhere [7].
- 120 Briefly, selected communities in Malaita province in the Solomon Islands were
- 121 randomised to MDA with open label ivermectin or ivermectin plus azithromycin.
- 122 All residents of these communities were eligible to participate. In both trial arms,

It is made available under a CC-BY 4.0 International license .

123 all participants were examined for scabies and offered a single oral dose of 124 ivermectin (200  $\mu$ g/kg of body weight). People with a contraindication to 125 ivermectin (pregnancy, breast-feeding, or weight <15 kg) were offered topical 126 permethrin instead. Those in whom a clinical diagnosis of scabies was made at 127 baseline were given a second dose of ivermectin 7–14 days later. Written 128 informed consent was obtained from adults and from a parent or guardian of 129 each child aged under 18 years. Assent was also obtained from children who 130 were able to provide it. The study was approved by the London School of 131 Hygiene & Tropical Medicine Ethics Committee, the Solomon Islands National 132 Health Ethics Committee and the Atoifi Adventist Hospital Ethics Committee. The 133 main trial was prospectively registered on clinicaltrials.gov (NCT02775617). 134 CDC staff did not interact with study participants or have access to identifying 135 information. 136 137 For the sub-study reported here, we collected dried-blood spots (DBS) from all 138 children aged less than 13 years at the baseline and 12-month surveys. We used

a fluorescent bead-based assay to test for antibodies against the recombinant
NIE antigen [6]. Briefly, serum was incubated with microspheres conjugated to
NIE, beads were washed to remove unbound immunoglobulin (Ig), and then
bound anti-NIE antibody was detected using biotinylated anti-human IgG+IgG4
antibody followed by streptavidin-phycoerythrin. Plates were run on a Luminex-

144 200 (Austin, TX USA) and results reported as median fluorescence intensity with

145 background subtracted. We used a receiver operating characteristic curve

146 analysis to determine cut-offs for seropositivity.

147

We conducted a before and after analysis to determine the effect of the MDA on prevalence of antibodies to *S. stercoralis*. Azithromycin has no known activity against *S. stercoralis* so we combined the two trial arms into a single group for analysis. We calculated the seroprevalence of *S. stercoralis* at baseline and twelve months, and the absolute and relative reduction at twelve months, along with associated confidence intervals and statistical tests of significance. Statistical analysis was conducted in R 3.4.2 (Vienna, Austria).

155

It is made available under a CC-BY 4.0 International license .

157	
158	<u>Results:</u>
159	In total, 1,291 people, including 553 0–12-year-olds were recruited and offered
160	treatment for scabies at the time of the baseline survey. We collected DBS from
161	539 of these children, representing more than $97%$ of children enrolled in the
162	trial. At the 12-month follow-up, 1,085 individuals (including 479 0–12-year-
163	olds) were seen, and we collected DBS from 448 children (94%). At baseline,
164	9.3% of the children were seropositive for antibodies to NIE, with a range across
165	the six study communities of 2.2% to 14.3% (Table 1). At the 12-month follow-
166	up, the overall prevalence had declined to $5.1\%$ with a range across the
167	communities of $2.1\%$ to $6.7\%$ . The absolute difference in prevalence between
168	baseline and 1 year was 4.2% (95% CI 0.7–7.5%) and the relative reduction was
169	45% (p = 0.019) The seroprevalence of antibodies to NIE was lower at the
170	follow-up visit than at baseline in all communities (Table). Neither the baseline
171	seroprevalence nor the magnitude of change following MDA was higher in
172	communities with a higher baseline prevalence of scabies where more
173	individuals would have received two doses of ivermectin at baseline (Table).

174

156

### 175 **Discussion**:

176 Our study adds to the limited available data on the impact of ivermectin MDA on 177 *S. stercoralis* prevalence. In the Northern Territory of Australia, a single round of 178 MDA with ivermectin reduced *S. stercoralis* seroprevalence from 21% at baseline 179 to 5% at 6 months, and a second MDA at month 12 further reduced the 180 seroprevalence to 2% at month 18 [8]. In Ecuador, the prevalence of *S. stercoralis* 181 fell from 6.8% to zero following multiple rounds of MDA conducted for the 182 purpose of onchocerciasis elimination[9]. We showed that in 6 communities in 183 Malaita, Solomon Islands, there was a decrease in seroprevalence of anti-NIE 184 antibodies one year after a single ivermectin MDA conducted for the purpose of 185 scabies control. 186

187 In the absence of a gold standard test for diagnosis of *S. stercoralis*, we used

188 serological markers that correlate well with more direct measures of infection.

It is made available under a CC-BY 4.0 International license .

189	Had we combined serology with other tests such as Kato-Katz or PCR on stool
190	specimens, we may have detected more cases. We were, however, consistent in
191	the measurement of exposure at both time points so are confident in the relative
192	change observed. As complete seroreversion of anti-NIE responses after
193	treatment may take more than one year[5], and it is not clear that all anti-NIE
194	positive individuals will serorevert [6], it is possible that we have under-
195	estimated the community-level effect of the intervention. Our study was not
196	powered to detect changes in seroprevalence in each individual community, and
197	although the changes were not statistically significant, there were declines in
198	seroprevalence in every community, consistent with our overall study finding.
199	
200	Data on the prevalence and distribution of STHs in the Solomon Islands are
201	limited. Two previous studies showed that hookworm, whipworm and
202	roundworm are common [10]. The baseline seroprevalence of <i>S. stercoralis</i> in 0–
203	12-year-olds in the current study was 9.3%, which is broadly similar to
204	prevalence of other STH species reported in the Solomon Islands [10]. Current
205	national deworming guidelines for the Solomon Islands are based on MDA with
206	albendazole, which is likely to have little or no impact on <i>S. stercoralis</i> .
207	Integrated strategies combining albendazole with ivermectin may therefore be
208	beneficial for control of <i>S. stercoralis</i> as well as providing enhanced effectiveness
209	against several STH species and allowing simultaneous control of scabies, which
210	is highly endemic in the region [3,7]. The current requirement for two doses a of
211	ivermectin, a week apart, for scabies MDA may represent a logistical barrier to
212	integration as single-dose treatment is effective against <i>S. stercoralis</i> [11]. Newer
213	anti-parasitic drugs such as moxidectin show promise as single-dose treatment
214	for scabies, strongyloidiasis and other STH [12,13].
215	
216	We have demonstrated that <i>S. stercoralis</i> is endemic in the Solomon Islands and
217	added to the limited data demonstrating that ivermectin MDA, here conducted
218	for the purpose of scabies control, can also reduce <i>S. stercoralis</i> seroprevalence.
219	These data highlight ancillary benefits that can be conferred by NTD control
220	programmes and suggest that STH programmes in this region may benefit from
221	the addition of ivermectin alongside albendazole

222

It is made available under a CC-BY 4.0 International license .

- **Disclaimer:** The authors alone are responsible for the views expressed in this
- article and they do not necessarily represent the views, decisions or policies of
- the institutions with which they are affiliated.
- 226
- 227

## 228 Funding:

- 229 The study was funded by a Wellcome Trust Clinical PhD fellowship to MM
- 230 (102807). The US CDC paid the laboratory costs. The funders did not have any
- role in the design, conduct or analysis of the study.
- 232

# 233 **Contributors**:

- MM wrote the first draft of the paper. CB, KA, EP conducted laboratory work.
  MM, HT, CK, JA, RA conducted fieldwork. MM, CB, KA, analysed the data. MM, JD,
  JKM, LR, MRM, DM, AWS, DCWM, AS designed and supervised the study. All
  authors revised the manuscript.
- 237 authors revised the 238

239

### 240 **Declaration of Interests**:

- 241 The authors have no competing interests to declare
- 242

# 243 **Supplementary Files**:

- 244 S1 Data Study Dataset
- 245 S2 Checklist Strobe Checklist
- 246
- 247

It is made available under a CC-BY 4.0 International license .

### 249 **References**:

250	1.	Grove DI. Human strongyloidiasis. Adv Parasitol <b>1996</b> ; 38:251–309.
251 252 253	2.	Krotneva SP, Coffeng LE, Noma M, et al. African Program for Onchocerciasis Control 1995–2010: Impact of Annual Ivermectin Mass Treatment on Off- Target Infectious Diseases. PLoS Negl Trop Dis <b>2015</b> ; 9:e0004051.
254 255 256 257	3.	Romani L, Marks M, Sokana O, et al. Efficacy of mass drug administration with ivermectin for control of scabies and impetigo, with coadministration of azithromycin: a single-arm community intervention trial. Lancet Infect Dis <b>2019</b> ; 19:510–518.
258 259 260 261	4.	Ravi V, Ramachandran S, Thompson RW, Andersen JF, Neva FA. Characterization of a recombinant immunodiagnostic antigen (NIE) from Strongyloides stercoralis L3-stage larvae. Mol Biochem Parasitol <b>2002</b> ; 125:73–81.
262 263 264	5.	Buonfrate D, Sequi M, Mejia R, et al. Accuracy of Five Serologic Tests for the Follow up of Strongyloides stercoralis Infection. PLoS Negl Trop Dis <b>2015</b> ; 9:e0003491.
265 266 267	6.	Mitchell T, Lee D, Weinberg M, et al. Impact of Enhanced Health Interventions for United States–Bound Refugees: Evaluating Best Practices in Migration Health. Am J Trop Med Hyg <b>2018</b> ; 98:920–928.
268 269 270 271	7.	Marks M, Toloka H, Baker C, et al. Randomized Trial of Community Treatment With Azithromycin and Ivermectin Mass Drug Administration for Control of Scabies and Impetigo. Clin Infect Dis Off Publ Infect Dis Soc Am <b>2019</b> ; 68:927–933.
272 273 274	8.	Kearns TM, Currie BJ, Cheng AC, et al. Strongyloides seroprevalence before and after an ivermectin mass drug administration in a remote Australian Aboriginal community. PLoS Negl Trop Dis <b>2017</b> ; 11:e0005607.
275 276 277 278	9 <u>.</u>	Anselmi M, Buonfrate D, Guevara Espinoza A, et al. Mass Administration of Ivermectin for the Elimination of Onchocerciasis Significantly Reduced and Maintained Low the Prevalence of Strongyloides stercoralis in Esmeraldas, Ecuador. PLoS Negl Trop Dis <b>2015</b> ; 9:e0004150.
279 280 281	10.	Harrington H, Bradbury R, Taeka J, et al. Prevalence of soil-transmitted helminths in remote villages in East Kwaio, Solomon Islands. West Pac Surveill Response J WPSAR <b>2015</b> ; 6:51–58.
282 283 284 285 286 287	11.	Buonfrate D, Salas-Coronas J, Muñoz J, et al. Multiple-dose versus single- dose ivermectin for Strongyloides stercoralis infection (Strong Treat 1 to 4): a multicentre, open-label, phase 3, randomised controlled superiority trial. Lancet Infect Dis <b>2019</b> ; 0. Available at: https://www.thelancet.com/journals/laninf/article/PIIS1473- 3099(19)30289-0/abstract. Accessed 25 September 2019.

288 289 290 291	12.	Bernigaud C, Fang F, Fischer K, et al. Preclinical Study of Single-Dose Moxidectin, a New Oral Treatment for Scabies: Efficacy, Safety, and Pharmacokinetics Compared to Two-Dose Ivermectin in a Porcine Model. PLoS Negl Trop Dis <b>2016</b> ; 10:e0005030.
292 293 294	13.	Barda B, Sayasone S, Phongluxa K, et al. Efficacy of Moxidectin Versus Ivermectin Against Strongyloides stercoralis Infections: A Randomized, Controlled Noninferiority Trial. Clin Infect Dis <b>2017</b> ; 65:276–281.
295		
296		

	Community					Total
	1	2	3	4	5	
Baseline seroprevalence % (n/N)	14.3% (19/133)	2.2% (2/90)	11.4% (8/70)	9.0% (13/144)	7.8% (8/102)	9.3% (50/539)
12-month follow-up Seroprevalence % (n/N)	5.2% (6/110)	2.1% (2/94)	6.9% (5/72)	6.7% (7/105)	4.9% (3/61)	5.1% (23/448)
Absolute reduction	9.1%	0.1%	4.5%	2.3%	2.9%	4.2%*
Relative reduction	36.4%	4.5%	60.5%	25.6%	37.2%	45.2%*
Baseline scabies prevalence	10.1%	12.2%	9.4%	7.1%	13.9%	10.5%

298 **TABLE 1**: *Strongyloides stercoralis* seroprevalence in children aged 0–12 before and after ivermectin mass drug administration

299 **\*** p < 0.05

It is made available under a CC-BY 4.0 International license .